PUBLICATIONS
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

Dr Jordi Bruix, MD, Prof Shukui Qin, MD, Prof Philippe Merle, MD, Alessandro Granito, MD, Prof Yi-Hsiang Huang, MD, György Bodoky, MD, Marc Pracht, MD, Prof Osamu Yokosuka, MD, Prof Olivier Rosmorduc, MD, Valeriy Breder, MD,
Prof René Gerolami, MD, Gianluca Masi, MD, Paul J Ross, FRCP, Tianqiang Song, PhD, Prof Jean-Pierre Bronowicki, MD,
Isabelle Ollivier-Hourmand, MD, Prof Masatoshi Kudo, MD, Prof Ann-Lii Cheng, MD, Prof Josep M Llovet, MD, Richard S Finn, MD, Marie-Aude LeBerre, MSc, Annette Baumhauer, MD, Gerold Meinhardt, MD, Prof Guohong Han, MD


The Lancet   2016